-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Moxifloxacin Hydrochloride and Sodium Chloride Injection Approved for Production
Category:
发布时间：2018-11-19
【概要描述】
On October 15, the Institute of Pharmaceutical Research once again celebrated a significant milestone: after five years of development, it obtained China’s first drug registration approval for moxifloxacin hydrochloride and sodium chloride injection packaged in non-PVC soft bags, with the trade name Yixinrui. Notably, both the formulation and its raw materials were independently developed by the company and were approved simultaneously.
On October 15, the Institute of Pharmaceutical Research once again celebrated a moment of achievement: after five years of effort, we have obtained my The first batch of drug registration approvals in China for moxifloxacin hydrochloride and sodium chloride injection packaged in non-PVC soft bags, with the trade name Yixin. Furthermore, both the formulation and the raw materials used are independently developed by the company and have been approved together.
Moxifloxacin is a fourth-generation quinolone with broad-spectrum and antibacterial activity due to its 8-methyl group. Oxofluoroquinolone antibacterial agents. Broad market prospects.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091